Maximizing the Public Health Benefit of Adverse Event Collection Throughout a Product’s Marketed Life Cycle By Debra A. McCurdy on 24 January 2008 Print:Email this postLike this postShare this post on LinkedIn On January 29, the FDA is holding a public workshop on “Maximizing the Public Health Benefit of Adverse Event Collection Throughout a Product’s Marketed Life Cycle.”
